UNION CITY, Calif.,
Nov. 11, 2015 /PRNewswire/ -- Abaxis,
Inc. (NasdaqGS: ABAX), a global diagnostics company manufacturing
point-of-care instruments and consumables for the medical,
research, and veterinary markets worldwide, announced
today that a five year supply contract has been signed for
Abaxis to provide VetScan HM5 Hematology analyzers and sell the
associated consumables to all Banfield Pet Hospital locations. As
part of the agreement, Abaxis expects to begin installations and
training at all Banfield hospitals in early 2016.
"At Banfield Pet Hospital, we believe in providing pets with the
highest quality care–part of that care is ensuring that we invest
in the right equipment and technology. The VetScan HM5 Hematology
analyzer will provide high quality in-house blood analysis for our
hospital teams, allowing them to make more accurate and efficient
recommendations for our pets and clients," said Karen Faunt, DVM, MS, Dipl. ACVIM, Vice
President of Medical Quality Advancement at Banfield Pet Hospital.
"Abaxis has been quick to respond to our needs as a practice and we
are appreciative of our ongoing partnership."
Don Wood, President and Chief
Operating Officer of Abaxis, stated, "We are pleased to partner
with one of the premier veterinary organizations in the world. We
are confident that our HM5 analyzer will complement Banfield's
extraordinary ability to provide the highest quality pet care
through their use of the point-of-care laboratory."
About Abaxis
Abaxis, Inc. is a worldwide developer, manufacturer and marketer
of portable blood analysis systems that are used in a broad range
of medical specialties in human or veterinary patient care to
provide clinicians with rapid blood constituent measurements.
Our mission is to improve the efficiency of care delivery to and
the quality of life of patients in the medical and veterinary
markets. We provide leading edge technology, tools and
services that support best medical practices, enabling physicians
and veterinarians to respond to the health needs of their clients
at the point of care while operating economical and profitable
practices. For more information, visit
http://www.abaxis.com.
About Banfield Pet Hospital®
Founded in Portland, Ore. in
1955, Banfield is the largest general veterinary practice in the
world. In 2007, Banfield joined the Mars, Inc. family of
businesses, and today it is more than 900 hospitals strong in
neighborhoods across the United
States and Puerto Rico.
More than 3,200 veterinarians at Banfield are committed to giving
pets the highest quality of veterinary care. Banfield hospitals
offer a full range of comprehensive medical services, computerized
medical records, preventive care plans for pets and extended
operating hours. Banfield Pet Hospital provides preventive care for
millions of pets each year through Optimum Wellness
Plans®.
Forward Looking Statements
This press release includes statements that constitute
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995 (the "Reform Act"),
including but not limited to statements related to Abaxis' cash
position, financial resources and potential for future growth,
market acceptance and penetration of new or planned product
offerings, and future recurring revenues and results of
operations. Abaxis claims the protection of the safe-harbor
for forward-looking statements contained in the Reform Act.
These forward-looking statements are often characterized by the
terms "may," "believes," "projects," "expects," "anticipates," or
words of similar import, and do not reflect historical facts.
Specific forward-looking statements contained in this press release
or in Abaxis' conference call may be affected by risks and
uncertainties, including, but not limited to, those related to
risks related to the transition of its U.S. medical sales to
Abbott, potential excess inventory levels and inventory imbalances
at the company's distributors, losses or system failures with
respect to Abaxis' facilities or manufacturing operations, the
effect of exchange rate fluctuations on international operations,
fluctuations in quarterly operating results, dependence on sole
suppliers, the market acceptance of Abaxis' products and services,
the continuing development of its products, required United States
Food and Drug Administration clearance and other government
approvals, risks associated with manufacturing and distributing its
products on a commercial scale free of defects, risks related to
the introduction of new instruments manufactured by third parties,
risks associated with competing in the human diagnostic market,
risks related to the protection of Abaxis' intellectual property or
claims of infringement of intellectual property asserted by third
parties and risks related to condition of the United States economy. Readers
should also refer to the section entitled "Risk Factors" in Abaxis'
annual report on Form 10‑K, and subsequently filed quarterly
reports on Form 10‑Q filed with the United States Securities and
Exchange Commission. Forward-looking statements speak only as
of the date the statements were made. Abaxis does not
undertake and specifically disclaims any obligation to update any
forward-looking statements.
Contact:
|
Abaxis,
Inc.
|
Lytham Partners,
LLC
|
|
Clint
Severson
|
Joe Dorame, Robert
Blum and Joe Diaz
|
|
Chief Executive
Officer
|
602-889-9700
|
|
510-675-6500
|
|
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/abaxis-inc-and-banfield-pet-hospital-enter-into-exclusive-five-year-supply-agreement-300176575.html
SOURCE Abaxis, Inc.